Iqvia Holdings Inc. Stock price

Equities

IQV

US46266C1053

Biotechnology & Medical Research

Delayed Nyse 04:01:55 2023-09-21 pm EDT Intraday chart for Iqvia Holdings Inc. 5-day change 1st Jan Change
199.18 USD -3.04% -6.47% -2.79%
Sales 2023 * 15,123 M Sales 2024 * 16,269 M Capitalization 36 474 M
Net income 2023 * 1,249 M Net income 2024 * 1,491 M EV / Sales 2023 *
3,17x
Net Debt 2023 * 11,529 M Net Debt 2024 * 10,680 M EV / Sales 2024 *
2,90x
P/E ratio 2023 *
30,0x
P/E ratio 2024 *
24,8x
Employees -
Yield 2023 *
-
Yield 2024 *
-
Free-Float70.52%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.04%
1 week-6.47%
Current month-10.53%
1 month-7.08%
3 months-6.85%
6 months+1.23%
Current year-2.79%
More quotes
1 week
197.64
Extreme 197.64
211.59
1 month
197.64
Extreme 197.64
227.14
Current year
177.00
Extreme 177
241.86
1 year
165.75
Extreme 165.75
241.86
3 years
146.00
Extreme 146
285.61
5 years
81.79
Extreme 81.79
285.61
10 years
40.10
Extreme 40.1
285.61
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 2016
Director of Finance/CFO 62 2020
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 51 2015
Chairman 61 2016
Director/Board Member 65 2015
More insiders
Date Price Change Volume
23-09-21 199.18 -3.04% 1,595,500
23-09-20 205.42 -1.66% 967,832
23-09-19 208.88 -0.22% 1,013,898
23-09-18 209.35 -1.11% 871,307
23-09-15 211.71 -0.59% 2,027,171

Delayed Quote Nyse, September 21, 2023 at 04:01 pm EDT

More quotes
Iqvia Holdings Inc. is one of the world's leading companies specializing in information, analytics, research and healthcare services based on technology solutions. Net sales break down by activity as follows: - development of contract research and clinical development solutions and services (54.5%): helping biopharmaceutical companies, medical researchers and healthcare professionals optimize their clinical studies, develop new therapeutic classes, identify treatment needs and assess the efficacy of pharmaceuticals with a view to improving clinical and scientific outcomes; - development of technology and analytics solutions (39.9%): services related to information, analysis, strategic consulting, marketing studies and short-term healthcare-market studies, business processes outsourcing, and management of medical-administrative databases, all aimed at optimizing the performance and commercial strategies of pharmaceutical companies and health workers; - integrated services (5.6%): development and implementation of customized solutions and customer engagement programs, healthcare services, scientific and medical services, etc. Net sales are distributed geographically as follows: Americas (49.4%), Europe and Africa (31.4%) and Asia/Pacific (19.2%).
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
B
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
199.18USD
Average target price
252.42USD
Spread / Average Target
+26.73%
Consensus
  1. Markets
  2. Equities
  3. Stock Iqvia Holdings Inc. - Nyse
-40% off #SeptemberDeals : Our subscriptions help you find hidden investment opportunities.
Subscribe
fermer